Teleflex Incorporated (TFX) AI Stock Analysis

Teleflex Incorporated designs, develops, and supplies single-use medical devices for critical care and surgical procedures. Its portfolio includes vascular access products sold under the Arrow brand, such as catheters, navigation systems, and intraosseous access systems. The company also offers interventional solutions for coronary and peripheral interventions, structural heart therapies, and cardiac assist applications. In addition, Teleflex delivers anesthesia, surgical, and interventional urology products, including airway and pain management tools, ligation clips, and the UroLift System for benign prostatic hyperplasia. It serves hospitals, healthcare providers, medical device manufacturers, and home care markets globally.

Teleflex saw revenue rise from $2.81B in FY2021 to $3.05B in FY2024 before dropping 34.6% to $1.99B in FY2025. This contributed to a 5-year revenue CAGR of -4.7% from FY2020 to FY2025. Gross margin held steady over this span, reaching 56.2% in FY2025. Operating margin was 12.8% in FY2025, but net income fell to -$905.6M with a net margin of -45.4%. For the trailing twelve months ended June 30, 2026, revenue stood at $2.25B with an operating margin of 10.1% and a profit margin of -45.8%. In the quarter ended June 30, 2026, revenue grew 28.9% year-over-year, while earnings declined 17.3%.

As of June 30, 2026, Teleflex held $300.2M in cash and short-term investments against total debt of $2.87B, resulting in net debt of $2.57B. Total assets were $6.79B, shareholders' equity was $2.90B, and the current ratio stood at 2.60 with a debt-to-equity ratio of 0.99. In FY2025, the business produced $340.7M in operating cash flow and $245.4M in free cash flow. Capital expenditures were $95.2M, while cash returned to shareholders included $300.0M in share buybacks and $60.3M in dividends paid.

At a last close of $130.43, Teleflex had a market capitalization of $5.53B and an enterprise value of $7.86B. The stock trades at a forward P/E of 11.0x, below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 2.5x compared to the peer median of 4.1x, while its EV/EBITDA stands at 30.2x compared to the peer median of 12.0x. Over the past year, Teleflex gained 6.5%, trailing the S&P 500 return of 16.8%. Over five years, the stock dropped 62.7% against an 83.0% gain for the index.

Teleflex pays a quarterly dividend with an annual forward payout of $1.36 per share, representing a dividend yield of 1.04% and a payout ratio of 15.5%. The company has paid dividends for 42 consecutive years, though annualized 5-year dividend growth was 0.0%. The most recent ex-dividend date was August 14, 2026.

Wall Street coverage includes 2 Strong Buy, 4 Buy, and 7 Hold ratings, with no Sell or Strong Sell ratings. The mean price target of $154.00 represents an 18.1% premium over the last close of $130.43. For the fiscal year ending December 31, 2026, analysts estimate revenue of $2.27B and EPS of $7.08. For the following fiscal year, 12 analysts project revenue of $2.37B and EPS of $10.94. The company beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Teleflex Incorporated (TFX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TFX income statement, TFX balance sheet, TFX key metrics, TFX analyst forecast, TFX chart. See the TFX stock overview for the latest quote and news.